1. Home
  2. FNGR vs BIAF Comparison

FNGR vs BIAF Comparison

Compare FNGR & BIAF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo FingerMotion Inc.

FNGR

FingerMotion Inc.

HOLD

Current Price

$0.14

Market Cap

11.0M

Sector

Technology

ML Signal

HOLD

Logo bioAffinity Technologies Inc.

BIAF

bioAffinity Technologies Inc.

HOLD

Current Price

$7.80

Market Cap

9.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FNGR
BIAF
Founded
2016
2014
Country
Singapore
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
11.0M
9.2M
IPO Year
2014
2022

Fundamental Metrics

Financial Performance
Metric
FNGR
BIAF
Price
$0.14
$7.80
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
★ 53.8M
7.0M
Earning Date
05-28-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
★ N/A
N/A
EPS
★ N/A
N/A
Revenue
★ $24,132,261.00
$7,900,000.00
Revenue This Year
N/A
$20.95
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
★ 14.49
52 Week Low
$0.13
$0.33
52 Week High
$2.20
$20.35

Technical Indicators

Market Signals
Indicator
FNGR
BIAF
Relative Strength Index (RSI) 39.91 53.20
Support Level N/A $1.07
Resistance Level $0.36 $12.48
Average True Range (ATR) 0.01 1.56
MACD 0.00 -0.37
Stochastic Oscillator 12.61 27.17

Price Performance

Historical Comparison
FNGR
BIAF

About FNGR FingerMotion Inc.

FingerMotion Inc is engaged in the provision of mobile payment and recharge services in the Chinese market. The Company organizes its operations across four primary areas: telecommunications products and services, marketplace platform and digital commerce infrastructure solutions, data and analytics platform solutions, and Advanced Technology And Platform Solutions. The company generates majority of revenue from telecommunications products and services segment. This segment includes mobile payment and recharge services, as well as enterprise messaging services such as short message services (SMS) and multimedia messaging services (MMS).

About BIAF bioAffinity Technologies Inc.

bioAffinity Technologies Inc develops noninvasive diagnostic laboratory tests to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis informed by machine learning, a form of artificial intelligence (AI). Its first commercial diagnostic test, CyPath Lung, identifies and analyzes cell populations using flow cytometry, including cancer and cancer-related cells, that indicate a malignancy in the lung. It is developing its flow cytometry platform to address the need to identify patients who can benefit from new and emerging therapies for asthma and chronic obstructive pulmonary disease with noninvasive precision diagnostic tests. The company is organized in two operating segments, Diagnostic Research and Development and Laboratory Services.

Share on Social Networks: